The Muscle Might Mismatch: Why New Weight-Loss Drugs Struggle to Deliver Functional Strength

The rapid emergence of GLP-1 receptor agonists (GLP-1-RAs) like semaglutide and tirzepatide has fundamentally altered the landscape of metabolic medicine. These medications, originally designed for type 2 diabetes management, have proven remarkably effective at inducing substantial weight loss, which in turn mitigates numerous health complications associated with obesity. However, a persistent clinical concern has accompanied this therapeutic success: the involuntary loss of lean mass. As patients shed pounds rapidly, they often lose not only adipose tissue but also skeletal muscle and bone density. While diet and resistance training remain the gold-standard recommendations for mitigating this risk, adherence rates are notoriously low, leaving the biotech industry to search for pharmacological solutions that could preserve or even build muscle during medical weight loss.

This pursuit has led to a series of high-profile clinical trials focusing on myostatin inhibition. Myostatin is a protein that acts as a negative regulator of muscle growth. The logic behind these therapies is intuitive: if you inhibit the "brake" on muscle growth, you should theoretically induce hypertrophy or prevent muscle wasting. Despite promising results in animal models and high-profile acquisitions in the biotech sector, a recurring and perplexing pattern has emerged: while these drugs effectively increase lean mass measurements, they consistently fail to deliver commensurate gains in physical strength or functional performance.

A Chronology of the Myostatin Pursuit

The scientific obsession with myostatin dates back to the late 1990s, when researchers identified mutations in the myostatin gene that resulted in "double-muscled" cattle and mice. These findings suggested that a simple pharmaceutical intervention could potentially revolutionize the treatment of sarcopenia, muscular dystrophy, and cachexia.

The clinical development of myostatin inhibitors has been characterized by a series of "near misses." Bimagrumab, a monoclonal antibody developed by Novartis, was one of the first major candidates to face rigorous testing. Originally intended for rare muscle-wasting diseases like sporadic inclusion body myositis (sIBM), the drug successfully demonstrated an increase in lean body mass across several trials. However, in Phase IIb studies, these mass gains failed to translate into improved performance on the 6-minute walking test or a reduction in fall risk for elderly patients. Despite these functional failures, the drug’s ability to reshape body composition kept it in the spotlight. In 2021, former Novartis employees formed Versanis Bio to advance the drug, leading to a massive $1.92 billion acquisition by Eli Lilly in 2023.

The most recent entry, apitegromab, has followed a similar trajectory. Initially investigated for spinal muscular atrophy (SMA), it showed inconsistent dose-response results in Phase III trials. The subsequent EMBRAZE trial, which paired apitegromab with the potent weight-loss drug tirzepatide, confirmed that the drug could indeed preserve lean mass. Patients on the combination therapy lost significantly less lean mass than those on tirzepatide alone. Yet, when subjected to standardized strength tests—such as grip strength and repetitive sit-to-stand repetitions—the apitegromab group showed no statistically significant functional advantage over the placebo group.

Supporting Data and the "Lean Mass" Paradox

The core of the issue lies in the definition of "lean mass" versus "functional muscle." In clinical trials, lean mass is often measured via Dual-energy X-ray absorptiometry (DEXA), a scan that calculates fat-free mass. However, this calculation includes water, bone, organs, and connective tissue, in addition to skeletal muscle.

The data from the EMBRAZE trial highlight this discrepancy starkly. While the apitegromab group retained approximately 4.5 pounds more lean mass than the placebo group, this extra mass provided no measurable benefit in strength. Similarly, in trials for human growth hormone (hGH) conducted over several decades, researchers repeatedly observed increases in total body lean mass without corresponding improvements in VO2max or muscular force.

Scientists have proposed several hypotheses to explain this "muscle-might mismatch." One theory suggests that while these agents increase the volume of muscle tissue, they may not necessarily increase the density of the contractile units (actin and myosin) required to generate force. Other researchers point to the possibility of "dysfunctional hypertrophy," where the muscle grows in size but fails to develop the necessary neuromuscular wiring or blood supply to function efficiently. There is also evidence from animal studies suggesting that inhibiting the activin-myostatin pathway may alter muscle fiber length or alignment in ways that do not optimize force production, effectively creating a "bulkier but weaker" muscle.

The Landscape of Future Interventions

As the pharmaceutical industry grapples with these paradoxical results, the search for a functional muscle-sparing agent continues. A notable deviation from the myostatin-inhibition strategy is the recent development of enobosarm, a selective androgen receptor modulator (SARM).

Unlike myostatin inhibitors, which focus on preventing muscle degradation or stimulating growth through signaling pathways, enobosarm targets androgen receptors in muscle and bone. Data from a Phase IIb trial presented by Veru Inc. showed that when combined with semaglutide, enobosarm preserved 71% more lean body mass than placebo and, crucially, showed a measurable impact on functional strength. Specifically, only 19.4% of patients on the enobosarm combination experienced a significant decline in stair-climb power, compared to 42.6% in the control group. These results suggest that targeting the androgen receptor might offer a more viable path toward maintaining physical function during weight loss than the myostatin pathway.

Broader Implications for Longevity and Public Health

The ongoing failure of myostatin-targeting drugs to produce functional strength gains poses a significant question for the future of obesity management. If a drug can change the shape of a patient’s body but cannot enhance their ability to navigate the physical world—to walk, stand, and lift—has the medical goal been met?

The consensus among exercise physiologists and longevity researchers remains clear: no pharmaceutical intervention currently available can replicate the multi-systemic benefits of resistance training. Beyond muscle hypertrophy, resistance training increases bone mineral density, improves insulin sensitivity, and enhances the strength of connective tissues—benefits that are not replicated by simply manipulating myostatin signaling. Furthermore, muscle strength is a more robust predictor of all-cause mortality than muscle volume or total lean mass.

For the millions of individuals currently using GLP-1-RAs to manage obesity, the medical community maintains that these drugs should be viewed as tools for weight management rather than substitutes for physical activity. While the biotech industry continues to chase a "magic bullet" that can prevent muscle loss without the requirement for exercise, the clinical reality remains that strength is a learned skill and a physiological adaptation to mechanical stress.

As the pharmaceutical industry moves forward with larger trials, such as the FORGE study for apitegromab, the objective will need to shift from merely observing changes in DEXA scans to proving that these drugs can meaningfully improve a patient’s quality of life and functional independence. Until such time, the "lean mass" preserved by these medications must be viewed as a baseline to be maintained, rather than a functional gain in power. The mystery of the "muscle-might mismatch" serves as a reminder that the human body is a highly integrated system, and its capacity for movement is governed by factors far more complex than a single signaling protein. Moving forward, the most effective strategy for the patient remains a combination of pharmacological metabolic support and the hard, manual labor of resistance training.